Checkpoint Therapeutics inc (CKPT) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access CKPT Annual Income Statement →
Income statement data covering Checkpoint Therapeutics inc–Mar 31 2024 offers a view into how Mar 31 2025's operating results have moved alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2025)
Q1 2025
(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing7.36
Research and Development Expense3.79
Total operating costs including COS11.15
Operating income / -loss-11.15
Net Interest Expense / -Income0.00
Investment Income, Interest0.00
Foreign Currency Transaction Gain (Loss), before Tax0.00
Other loss / -income0.00
Total costs & expenses11.21
Income & Taxes
Income / -loss before income taxes-11.21
Income after income taxes-11.21
Income / -loss from continuing operations-11.21
Net income / -loss-11.21
Income / -loss to shareholder-11.21
EBIT-11.21
EBITD-11.21
EBITDA-11.21
Earnings Per Share
Basic EPS (excl. extra items)-0.19
Basic Net EPS-0.19
Basic shares outstanding (Mill. of Units)59.82
Diluted Net EPS-0.19
Diluted average shares (Mill. of Units)59.82
4 historic quarters locked

Sign in to unlock the full Checkpoint Therapeutics inc income statement history.

About Checkpoint Therapeutics Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.